We report a 75-year-old man who was initially suggested to have acute leukemia. The hemoglobin level was 3.8 g/dL, white cell count was 7,700/µL with an absence of mature neutrophils and 69.0% leukemic cells, and platelet was 0.4 × 10(4)/µL. Coombs' antiglobulin test was positive. Leukemic cells were CD5(-), CD10(+), CD20(+), CD23(-), and IgG/λ(dim+). The bone marrow consisted of normal hematopoietic precursors, whereas fluorescence in situ hybridization detected the BCL2/IgH fusion gene. He was treated with rituximab-containing chemotherapy, resulting in the resolution of pancytopenia. The underlying disease was a leukemic B-cell tumor with t(14;18)(q32;q21), and the pancytopenia was mainly caused by autoimmune mechanisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.50.4197 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Acquisition of Primary Ph Bone Marrow Cells and Establishment of Ph B-ALL Mouse Model].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Blood Disease Institute, Xuzhou Medical University,Xuzhou 221000, Jiangsu Province, China.
Article Synopsis
- The objective of the study was to harvest primary Philadelphia chromosome-positive (Ph) cells from B-acute lymphoblastic leukemia (B-ALL) and create a B-ALL mouse model.
- Methods included infecting bone marrow cells from C57BL/6J mice with a retrovirus, followed by the transplantation of transfected cells into irradiated mice, resulting in the establishment of multiple generations of Ph cells.
- The results showed significant health deterioration in the mice post-transplant, with pathological features such as weight loss and leukemic cell infiltration in the liver, confirming the successful creation of a B-ALL mouse model through progressive passages of Ph cells.
A Practical Guideline for MicroRNA Sequencing Data Analysis in Chronic Lymphocytic Leukemia.
Methods Mol Biol
December 2024
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. They have been associated with several diseases and cancers, including chronic lymphocytic leukemia (CLL). CLL is the most common form of adult leukemia, and its pathogenesis is driven by the deletion of miRNAs, such as the miR-15a/16-1 cluster.
View Article and Find Full Text PDFTranscriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels.
Blood Cancer J
December 2024
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Historically, CLL prognostication relied on disease burden, reflected in clinical stage. Later, chromosome abnormalities and genomics suggested several CLL subtypes which were aligned with response to therapy. Gene expression profiling data identified pathways associated with CLL progression.
View Article and Find Full Text PDFMolecular signatures associated with venous thromboembolism in children with acute lymphoblastic leukemia.
J Thromb Haemost
December 2024
Department of Pediatrics, Centre Hospitalier Universitaire de Québec - Centre Mère-Enfant Soleil, Quebec City, Quebec, Canada; Centre de Recherche du Centre Hospitalier Universitaire de Québec, Quebec City, Quebec, Canada. Electronic address:
Background: Venous thromboembolism (VTE) is a frequent complication of childhood acute lymphoblastic leukemia (ALL).
Objectives: We aimed to identify molecular markers and signatures of leukemia microenvironment associated with VTE in childhood ALL, by dual-omics approach of gene expression (GEP) and DNA-methylation profiling.
Patients/methods: Eligible children were aged 1-21 years old with newly diagnosed ALL enrolled on the Dana Farber Cancer Institute 16-001 trial with available RNA sequencing data from bone marrow at diagnosis.
Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.
Cancer Med
December 2024
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Backgroud: The high cost of blinatumomab in full doses of full treatments has led to dose reduction and fewer treatment cycles for most patients in China. With current needs for cost-efficiency and resource management in health care, we retrospectively evaluated the clinical effects of short-course blinatumomab treatment for R/R Ph- B-ALL at our center.
Methods: Blinatumomab was administered with 24-h continuous intravenous infusion (9 μg/day for the first 3 days and 28 μg/day for 6-10 days).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!